Table 1.
Comparison of CYP3A5 polymorphisms with the characteristics
| Characteristics | CYP3A5*1/*1 | CYP3A5*1/*3 | CYP3A5*3/*3 | P |
|---|---|---|---|---|
| Number of patients | 12 | 48 | 41 | 0.12 |
| Recipient age in years (mean) | 34.16 | 32.2 | 32.58 | 0.081 |
| Donor age in years (mean) | 47.91 | 49.92 | 49.13 | 0.11 |
| Male:Female | 10:2 | 38:10 | 37:4 | 0.11 |
| Live donors | 58.33% | 70.83% | 73.17% | 0.071 |
| Mean creatinine (mg/dL) | 1.27 | 1.31 | 1.45 | 0.088 |
| Tacrolimus dose (mg/day) (mean±SD) | 6.54(±2.17) | 5.08(±1.85) | 2.66(±1.21) | <0.001 |
| Tacrolimus level (ng/mL)-(mean) | 6.01(±4.54) | 5.84(±1.78) | 7.46(±2.99) | 0.019 |
| L/D ratio (ng/mL/mg/kg/day) | 48.99 | 68.93 | 181.3 | <0.001 |
| Induction treatment | 50% | 35.42% | 29.27 | 0.986 |
| Rejections | 3 (25%) | 15 (31.3%) | 4 (9.76%) | 0.047 |
| 18 (30%) | 4 (9.76%) | 0.016 | ||
| CNI toxicity | 1 | 2 (4.2%) | 6 (14.6%) | 0.158 |
| 3 (5%) | 6 (14.6%) | 0.039 | ||
CYP3A5: Cytochrome P450 family 3 subfamily A member 5